Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is a clinical-stage biotech company with a promising Precision Endocrine Peptide platform technology, optimized for extended time-action profiles and consistent drug concentration with lower dosing frequencies. With their lead compound, MBX 4291, showing a differentiated pharmacokinetic profile supporting a once-monthly dosing paradigm and potent weight loss with good GI tolerability, the potential for commercial success in the obesity market is high. The company's strong pipeline, including an amycretin prodrug candidate and a triple-agonist (GLP-1/GIP/glucagon) development candidate, further increases its potential for success. Despite risks such as clinical trial results and cash needs, the company's potential for commercial success and its pipeline developments make it a strong buy with a target price of $70 per share.

Bears say

MBX Biosciences is facing potential risks to its investment thesis, including pipeline risk as data from patients in their target indications is needed to move programs forward and no assurance that future data will continue to be positive. Additionally, commercial risk exists as there is one approved drug for their lead indication and no approved drug for post-bariatric hypoglycemia, making the eventual market opportunity uncertain. Lastly, the company will continue to incur net losses until commercialization and may need to raise additional capital, potentially impacting shareholder value.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.